| DIRECT COMPETITOR COMPARISON | |
| CVM | CLDX | Pvt1 | Pvt2 | Industry | | Market Cap: | 192.92M | 144.11M | N/A | N/A | 100.26M | | Employees: | 30 | 78 | N/A | N/A | 68 | | Qtrly Rev Growth (yoy): | 761.40% | 70.90% | N/A | N/A | 19.70% | | Revenue (ttm): | 50.09K | 13.44M | N/A | 13.85B1 | 14.01M | | Gross Margin (ttm): | 100.00% | 100.00% | N/A | N/A | 65.67% | | EBITDA (ttm): | -9.98M | -28.69M | N/A | N/A | -12.30M | | Oper Margins (ttm): | -20,694.52% | -233.99% | N/A | N/A | -149.46% | | Net Income (ttm): | -11.10M | -31.04M | N/A | 3.58B1 | N/A | | EPS (ttm): | -0.090 | -1.961 | N/A | N/A | -0.33 | | P/E (ttm): | N/A | N/A | N/A | N/A | 16.37 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.31 | | P/S (ttm): | 3851.28 | 10.73 | N/A | N/A | 9.35 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | 0.00% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | 0.00% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | 0.00% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | 0.00% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | 0.00% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | 0.00% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | 0.00% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | 0.00% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | 0.00% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | 0.00% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | 0.00% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | 0.00% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | 0.00% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | 0.00% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | 0.00% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | 0.00% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | 0.00% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | 0.00% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| | CLDX | | CELLDEX THERAPEUTICS, INC. Financials Wed, Nov 11 -
EDGAR Online Financials | | | CLDX | | CELLDEX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Fri, Nov 6 -
EDGAR Online | | | CLDX | | Celldex Therapeutics to Present at Merriman Curhan Ford's Investor Summit 2009 Thu, Nov 5 -
Business Wire | | | CLDX | | New Star Analyst Rankings for Celldex Therapeutics, Inc Thu, Nov 5 -
StarMine | | | CLDX | | CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an Wed, Nov 4 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|